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Background: The main objective of this study was to estimate the prevalence of human papillomavirus-DNA 
(HPV-DNA) in the saliva of sexually active women with HPV-related cervical intraepithelial neoplasias (CIN) 
and compare the findings with a healthy control group. The secondary objectives were: 1) to determine the con-
cordance between genital and oral HPV types in sexually active women with HPV-related CIN; 2) to analyze 
whether sexual habits influence the presence of HPV-related CIN; 3) to determine whether sexual habits influence 
the presence of oral HPV.
Material and Methods: Saliva samples were collected from 100 sexually active women, 50 with HPV-related CIN 
and 50 healthy subjects presenting normal cytology. PCR assay was used to detect HPV-DNA.
Results: The prevalence of oral HPV infection in saliva samples was 14% in women with HPV-related CIN, while 
in the healthy group it was 12%, without statistically significant difference (p=0.766). As for the concordance 
between genital and oral HPV types in women with HPV-related CIN, concordance was only observed for HPV-
16, whereby among 22 women with genital HPV-16, only one (4.54%) also presented oral HPV-16. Regarding the 
possible influence of sexual habits on the presence of cervical pathology and presence of oral HPV, it was found 
that marital status, age at first intercourse, number of lifetime sexual partners, and condom use are related with 
the presence of cervical pathology (p<0.001; p=0.017; p=0.002; and p<0.001, respectively); condom use was also 
found to be related to the presence of oral HPV (p<0.001).
Conclusions: The prevalence of HPV-DNA in the saliva of sexually active women with HPV-related CIN is similar 
to healthy women. The concordance between genital and oral HPV types is low. Both the presence of cervical pathol-
ogy and the presence of oral HPV are related to sexual habits. Wider sample size is required to confirm this results.
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Introduction
Cervical cancer is the second most common cancer 
among women around the world, and is more frequent 
(>85% of cases) in developing countries (mainly Asia, 
Africa, and South America) (1). It is the seventh cause 
of cancer-related death in Europe. Higher rates occur in 
Eastern Europe, while lower rates are found in South-
ern Europe and the Nordic countries. Spain is among 
the populations at low/moderate risk of cervical cancer, 
with an incidence rate of 7.1 cases per 100.000 wom-
en per year, diagnosing 1.948 cases and recording 712 
deaths annually from this type of cancer (2). Infection 
by human papillomavirus (HPV) has been recognized 
as an etiological factor for developing cervical carci-
noma (3). HPV is a small DNA virus with a circular 
double-stranded chain of 7,900 base-pairs. The viral 
particles are proteinic and non-enveloped, very stable 
under adverse conditions in an external medium with 
a capacity for enduring infection. It has a diameter of 
55-60 nm, with a viral capsid consisting of 72 cap-
somers in icosahedral arrangement. The virus is able 
to infect many regions of the human body, generating 
multiple clinical manifestations that range from benign 
hyperplasic lesions to neoplasias of the anogenital re-
gion, skin, oral cavity, and pharynx (4). Currently, it is 
believed that there are more than 150 different types 
of  HPV in existence (with distinct variations and sub-
types), and depending on the oncogenic capacity of 
each type (capacity to establish persistent infection, 
and promote cell proliferation, altering the DNA of host 
cells), they are classified by type as: high oncogenic risk 
[16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59]; probable 
high risk [26, 53, 66, 68, 73 and 82]; and low risk [6, 11, 
13, 40, 42, 43, 44, 54, 61, 70, 72, 81, 89, and CP6108] (5). 
Approximately a third of these are able to infect the epi-
thelium of the genital tract and have been identified as a 
definitive human carcinogen for six types of cancer: of 
the cervix, penis, vulva, vagina, anus, and oropharynx 
(including the base of the tongue and tonsils) (6).
HPV infection of the cervix, is usually related to the 
appearance of different degrees of cervical intraepithe-
lial neoplasias (CIN), which range from CIN I lesions 
(slight dysplasia: 1/3 of the cervical cells are abnormal) 
that retain the capacity to maintain a complete life cycle 
with virion release; CIN II (moderate dysplasia: 2/3 of 
cells are abnormal); and CIN III (severe dysplasia/carci-
noma in situ: almost all the cervical cells are abnormal). 
The two latter classifications produce an increase in the 
expression of two proteins with oncogenic capacity: the 
E6 and E7 (viral proteins that favor DNA cell attach-
ment); these facilitate the accumulation of mutations in 
the cell genome, which allows the cancer to progress 
(7). Nevertheless, although infection of the cervix by 
HPV is relatively common (up to 80%), cancer is rare 
(<1%) (8).
In general, infection by HPV among young sexually 
active women is frequent, but clears up in 80% of cases 
due to effective immune responses, mediated by CD4+ 
Th1 response. HPV has various immune evasion sys-
tems, as its life cycle is exclusively epithelial and there 
are no viraemic phases, no cell destruction, and viral 
replication and virion release is not accompanied by 
inflammatory processes. Moreover, virion-producing 
cells that express large amounts of viral antigens are 
located on the surface of the epithelium away from the 
immune cells, which are also scarce in the cervical 
area (9). The key event for progress towards neoplasia 
could be the deregulation of transforming viral protein 
expression (E6 and E7), which would lead to increased 
cell proliferation in lower epithelial layers and an inca-
pacity to repair secondary mutations in host cell DNA. 
CIN III generally progresses to cancer in lesions that 
contain integrated copies of the viral genome, in which 
E7 expression is high. In these lesions with high E6 
oncogenic activity, degradation of the p53 tumor sup-
pressor gene is produced, inducing the expression of 
cyclin-dependent kinase inhibitors p16 (p16INK4a), 
p21 and p27 (10).
Regardless of whether or not HPV clears up by cervical 
auto-immune response, sexual behavior has changed 
in recent decades, the age of sexual initiation has de-
creased, and lifetime numbers of sexual partners have 
increased. There has also been a rise in the frequency 
of oral-to-genital sex, which, in the U.S.A. is more 
common among Whites (75%), followed by Hispanics 
(63%), and Afro-Americans (62%) (11). These changes 
in sexual habits have increased the risk of infection by 
HPV, not only genitally but also in the oral cavity with 
particular tropism in the lymphoid tissues, especially 
the epithelium coating the tonsillar crypts and the base 
of the tongue that form part of the Waldeyer ring. In 
fact, there are certain similarities to the cervix, as both 
proceed from the embryonic endoderm and are epithe-
lia with many invaginations, which could favor anti-
gen capture and processing, facilitating viral access to 
basal cells.
Over 650.000 patients are diagnosed with head and neck 
squamous cell carcinoma (HNSCC) worldwide every 
year and over 350,000 die from it (12). Increased inci-
dence of oropharyngeal carcinoma in recent years, spe-
cifically in the amigdala and the base of the tongue (13), 
in addition to the fact that research has linked HSCNN 
to HPV, especially HPV-16 (14,15), might suggest that 
sexually active women with HPV-related genital lesions 
are at greater risk of presenting some type of HPV in 
the oral cavity.
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The main aim of this study was to estimate the prev-
alence of HPV-DNA in the saliva of sexually active 
women with HPV-related CIN compared with a healthy 
group. The secondary objectives were: 1) to determine 
the concordance between genital and oral HPV types 
in sexually active women with HPV-related CIN; 2) to 
analyze whether sexual habits influence the presence of 
HPV-related CIN; and 3) to determine whether sexual 
habits influence the presence of oral HPV.
Material and Methods
- Recruitment and patient characteristics
The study protocol was approved by the University 
of Murcia Ethics Committee and was carried out be-
tween May 2015 and February 2018 at the Obstetrics 
and Gynecology Unit, Santa Lucía University Hospital, 
Cartagena (Spain). Subjects were treated according to 
guidelines established by the Declaration of Helsinki 
for medical research involving human subjects. All 
subjects provided their informed consent to participate. 
Subjects were recruited applying inclusion criteria re-
corded in the hospital database: women with and with-
out HPV-related CIN. The entire protocol was carried 
out by a single clinician.
Inclusion criteria in the study group were as follows: 
patients aged over 18 years, sexually active women with 
HPV-related CIN, patients willing to provide informed 
consent to take part in the study.
For the control group the inclusion criteria were: pa-
tients aged over 18 years, sexually active women with-
out HPV-related CIN, patients willing to provide in-
formed consent to take part in the study.
None of the patients who fulfilled the inclusion criteria 
and were invited to take part in the trial refused to do 
so. To calculate a representative sample size, a power of 
80% was required (5% alpha level). A total of 50 sexual-
ly active women with HPV-related CIN and 50 sexually 
active women without HPV-related CIN were included 
in this transversal clinical study.
Having received their informed consent in writing, a 
detailed anonymous questionnaire was administered in 
order to collect information about age, smoking, drink-
ing, and sexual habits.
- Sample collection and HPV-DNA detection
All saliva samples (n=100) were collected under equal 
conditions (first thing in the morning, instructing sub-
jects not to eat or drink for 90 minutes before sample 
collection). Patients were placed in a relaxed position 
and looking downwards. Patients were asked to rinse 
the mouth vigorously and gargle with 10 ml normal sa-
line for a total of 30 seconds (10 seconds rinse, 5 sec-
onds gargle, 10 seconds rinse, and 5 seconds gargle). 
Specimens were collected in sterile tubes and refriger-
ated to minimize degradation of salivary proteins un-
til further processing. The saliva samples were centri-
fuged at 2000 rpm at 4ºC for 10 min, 2 ml supernatant 
saved, followed by re-suspension of the cell pellet in 10 
ml PBS, which was centrifuged at 2000 rpm at 4ºC for 
10 min, then re-suspended in 3 ml PBS, and split into 
two aliquots. All samples were stored locally at -80ºC 
until DNA purification, amplification, and HPV-DNA 
detection.
All samples were analyzed by the same geneticist in a 
blinded fashion. DNA was purified from all samples by 
use of a Puregene DNA Purification Kit (Gentra Sys-
tems, Minneapolis, Minnesota, USA) (16). The pres-
ence of HPV genomic DNA in saliva samples was 
detected by polymerase chain reaction (PCR) amplifica-
tion using the PGMY09/11 L1 consensus primer system 
(17); the type was specified by hybridization to an HPV 
probe array containing 32 HPV types (high oncogenic 
risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59; prob-
able high risk: 26, 53, 66, 68, 73 and 82; and low risk: 6, 
11, 13, 40, 42, 43, 44, 54, 61, 70, 72, 81, 89, and CP6108) 
(6), and β-globin (Roche Molecular Systems, Alameda, 
California, USA) (18).
- Statistical analysis
Data were analyzed using the SPSS 20.0 statistics pro-
gram (SPSS® Inc, Chicago, IL, USA). A descriptive 
study was made of each variable. The Kolmogorov-
Smirnov normality test and Levene’s homogeneity of 
variance test were applied; the data showed normal dis-
tribution and so were analyzed using parametric tests. 
Associations between the different qualitative variables 
were studied using Pearson’s chi-squared test. Asso-
ciations between different quantitative variables were 
studied using Student’s t-test for two related samples. 
Adjusted odds ratios and confidence intervals were cal-
culated using multiple logistic regression models con-
sidering the binaries “presence of HPV-related CIN” 
and “presence of oral HPV” as the outcome variables, 
and using marital status, age at first intercourse, num-
ber of lifetime sexual partners, oral-to-genital sex, and 
condom use as covariates. Statistical significance was 
accepted for p≤0.05.
Results
A total of 100 sexually active women, 50 with HPV-
related CIN (with a mean age of 34.54 ± 7.66) and 50 
healthy control subjects without HPV-related CIN 
were included in this transversal clinical study. Mean 
patient age was 36.92 ± 6.69. Both groups were ho-
mogenous in terms of age (p=0.101), educational level 
(p=0.505), smoking (p=0.683), and alcohol consump-
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practiced oral-to-genital sex (92% compared with 70%), 
had had some  sexually transmitted infection (16% com-
pared with 4%), and a lower percentage of women in this 
group used condoms (34% compared with 74%); with 
statistically significant differences (p<0.001; p=0.046; 
p=0.004; p=0.001; p=0.005; p=0.046; and p=0.001, re-
spectively) (Table 1).
tion (p=0.517). Nevertheless, a higher percentage of 
women with HPV-related CIN were single or not in a 
stable couple relationship (88% compared with 34% of 
control subjects), had had >4 children (16% compared 
with 4%), had had their first sexual intercourse aged ≤16 
years (30% compared with 10%), had had a number of 
lifetime sexual partners ≥2 (98% compared with 60%), 
Characteristics Group with HPV-related CIN**
(n=50)
Group without HPV-related CIN**
(n=50)
p-value
Age: mean ± SD* 34.54 ± 7.66 36.92 ± 6.69 0.101
Education level: n (%)
   Primary
   Secondary









   Smoker






Alcohol consumption: n (%)
   Yes






Marital status: n (%)
   Married or in stable couple






Number of children: n (%)
   1-3






Age at first intercourse: n (%)
   >13
   14-16
   17-20










Number of lifetime sexual partners: n (%)
   1
   2-5
   6-10
   11-20












Oral-to-genital sex: n (%)
   Yes






Contraceptive use: n (%)
   None
   Condom
   Contraceptive pill










Sexually transmitted infections: n (%)
   None
   Chlamydia
   Syphilis
   Gonorrhea












* SD = standard deviation
** CIN: cervical intraepithelial Neoplasias
Table 1: Comparison of demographic characteristics in study groups: educational level, sexual history and habits between study groups (Stu-
dent t-test and Pearson χ2).
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The prevalence of HPV-DNA in saliva was found to be 
similar between the two groups, 14% in women with 
HPV-related CIN compared with 12% in women without 
HPV-related CIN, with no statistically significant differ-
ence (p=0.766). Only two (4%) women in the group  with 
HPV-related CIN presented more than one type of oral 
HPV (two types) and only one women (2%) in the healthy 
control group, without statistically significant difference 
(p=0.842). When oral HPV types were compared be-
tween groups, nine different types were diagnosed  in 
seven women with HPV-related CIN and HPV-DNA in 
saliva, the most common type being 45 but no signifi-
cant difference was found in comparison with the control 
group (33.33% compared with 14.28%; p=0.308). In the 
same way, it was observed that of the seven types diag-
nosed in six of the women without HPV-related CIN and 
HPV-DNA in saliva, the most frequently occurring type 
was 39 but without significant difference in compari-
son with its presence in women with HPV-related CIN 
(28.57% compared with 22.22%; p=0.853) (Table 2).
Characteristics Group with HPV-related CIN*
(n=50)
Group without HPV-related CIN*
(n=50)
p-value
Prevalence of oral HPV: n (%) 7 (14) 6 (12) 0.766
Oral HPV + single or multiple: n (%)
   None
   Single








Oral HPV characteristics Group with HPV-related 
CIN:
Oral HPV types found (n=9)
Group without HPV-related 
CIN:
Oral HPV types found (n=7)
p-value
High-risk HPV types in cervix: n (%)
   16
   18
   31
   33
   35
   39
   45
   51
   52
   56
   58





































Probable high-risk HPV types in cervix: n (%)
   26
   53
   66
   68
   73



















Low-risk HPV types in cervix: n (%)
   6
   11
   13
   40
   42
   43
   44
   54
   61
   70
   72
   82
   89











































* CIN: cervical intraepithelial Neoplasias
Table 2: Comparison of oral HPV characteristics between groups (Pearson χ2 test).
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Regarding the characteristics of genital HPV in women 
with HPV-related CIN, 50% presented multiple types, 
making a total of 93 types, the most common being 
type 16 (23.65%) (Table 3). When the concordance of 
genital and oral HPV types in group with HPV-relat-
ed CIN was analyzed, among 22 women with genital 
HPV-16, only one (4.54%) also presented oral HPV-16; 
for the remaining 92 types genital HPV types, no con-
cordance was obtained between cervical and oral HPV 
types (Table 4).
Characteristics Group with HPV-related CIN*
(n=50)
Cervical Intraepithelial Neoplasia (CIN): n (%)
   CIN I
   CIN II




Genital HPV + single or multiple: n (%)
   Single
   Multiple
25 (50)
25 (50)
Genital HPV characteristics Genital HPV types
(n=93)
High-risk HPV types in cervix: n (%)
   16
   18
   31
   33
   35
   39
   45
   51
   52
   56
   58













Probable high-risk HPV types in cervix: n (%)
   26
   53
   66
   68
   73







Low-risk HPV types in cervix: n (%)
   6
   11
   13
   40
   42
   43
   44
   54
   61
   70
   72
   82
   89















* CIN: cervical intraepithelial Neoplasias
Table 3: Description of cervical intraepithelial neoplasia and genital HPV characteristics in group with HPV-related CIN.
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When sexual habits were analyzed to determine wheth-
er these exert any influence on the presence of HPV-
related CIN, it was found that marital status, age at first 
intercourse, number of lifetime sexual partners, and 
condom use were all related to presence of HPV-related 
CIN (OR: 0.07; 3.85; 0.20; and 5.52 respectively) (95% 
CI: 0.02-0.19; 1.27-11.63; 0.07-0.56; and 2.33-13.07 re-
spectively) (p<0.001; p=0.017; p=0.002; and p<0.001 
respectively).
Lastly, when sexual practices (marital status, age at first 
intercourse, number of lifetime sexual partners, oral-to-
genital sex, and condom use) were analyzed to deter-
mine whether they had any influence on the presence 
of oral HPV, only condom use was found to be related 
to the presence of oral HPV (OR 45.00, 95% CI 9.71-
208.59, p<0.001).
Discussion
HPV infection is the most common sexually transmit-
ted disease, which may affect as many as 70% of young 
women (6). Among women infected with HPV, a small 
number will go on to develop CIN (I, II, or III), and 
eventually cancer (8). When cytological screening de-
tects an abnormality, this will be further investigated 
by means of a colposcopy with targeted cervical bi-
opsy, HPV-DNA analysis, and endocervical curettage 
if considered necessary. The therapeutic procedures for 
dealing with CIN range from treatments that destroy 
tissue (cryoagulation or laser vaporization) to the most 
commonly used excisional treatment using conization, 
which consists of the removal of a cone-shaped wedge 
of tissue from external part of the uteris or exocervix 
(the base of the cone) and an internal part correspond-
ing to the cervical canal or endocervix (the tip of the 
Genital HPV characteristics Genital HPV types
(n=93)
Patients with the same HPV type in mouth
Yes: n (%) No: n (%)
High-risk HPV types in cervix: n (%)
   16
   18
   31
   33
   35
   39
   45
   51
   52
   56
   58





































Probable high-risk HPV types in cervix: n (%)
   26
   53
   66
   68
   73



















Low-risk HPV types in cervix: n (%)
   6
   11
   13
   40
   42
   43
   44
   54
   61
   70
   72
   82
   89











































Table 4: Concordance of genital and oral HPV types in group with HPV-related CIN.
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cone) (19). Recent decades have seen changes in sexual 
behaviors, with increased practice of oral-to-genital sex 
(11), which suggests that women with HPV-related CIN 
may be at greater risk of presenting some type of HPV 
in the oral cavity. This possibility, together with the 
fact that oral HPV is increasingly found to be related 
to HSCNN (14,15), are the reasons behind the present 
study’s objectives.
The main aim was to estimate the prevalence of HPV-
DNA in the saliva of sexually active women with HPV-
related CIN compared with a healthy control group. 
Prevalence was found to be similar in both groups, 14% 
in women with HPV-related CIN compared with 12% in 
women without HPV-related CIN, without statistically 
significant difference (p=0.766). Similar results have 
been obtained by other authors such as Adamopoulou 
et al., (20) who analyzed saliva samples using PCR of 
43  sexually active women without HPV-related CIN; 
oral HPV prevalence was 11.6%, almost identical to the 
prevalence found in the present control group of healthy 
subjects and very similar to the study group of women 
with HPV-related CIN. But others, such as Siani et al. 
(21), who analyzed saliva samples from 70 sexually 
active women with cervical cancer, found a very low 
prevalence of oral HPV (4 out of 70, 5.71%). But other 
studies such as Visalli et al. (22), who, like the present 
study, investigated the prevalence of HPV in the saliva 
of 100 women with HPV cervical lesions compared 
with a healthy control group of 25 women with normal 
cytology, obtained greater prevalence in women with 
HPV cervical lesions than the control group (24% com-
pared with 8%), with statistically significant differences 
(p≤0.05). Likewise, Giraldo et al., (23) compared the 
prevalence of HPV in the oral cavity among 70 women 
presenting histopathologically confirmed clinical HPV 
lesions in the genital region and 70 with HPV-related 
genital lesions, obtaining much higher prevalence 
among women with HPV lesions in the genital region 
(37.1% compared with 4.3%), with strongly significant 
difference  (p<0.001).
This large discrepancy in results for the possible great-
er prevalence of oral  HPV in sexually active women 
with HPV-related CIN reported in the literature, could 
be related to three main aspects: firstly, the differences 
in the populations studied; secondly, methodological 
differences between studies; and thirdly, variations in 
sexual practices (20). Regarding populations, the pub-
lished literature includes a diversity of populations and 
specimen types; nevertheless, co-infection of multiple 
anatomical sites in the same individual can be attrib-
uted to factors such as genetic predisposition or inad-
equate immune response. Any alteration in immunity, 
whether general or local, can favor the colonization, 
replication and persistence of HPV in regions such as 
the oral cavity (24). As for methodology, there is great 
variability in the screening efficacy of HPV detection 
methods among the articles published. In this sense, in 
the study by Adamopoulou et al., (20) which obtained a 
prevalence of oral en HPV in sexually women without 
HPV-related CIN of 11.6% using PCR, this prevalence 
increased in the same group  to 44.2% with nested PCR. 
To achieve homogeneity among this type of study, it is 
important that sexual behaviors that may affect the ap-
pearance of co-infection at both anatomic sites (cervix 
and oral cavity), such as a history of oral-to-genital con-
tact and condom use during this contact, should be re-
corded in all studies, as these and other sexual practices 
could increase or decrease the prevalence of oral HPV 
in sexually active women both with and without HPV- 
related CIN (25,26). In this context, one of the main 
limitations of the present work was the small sample 
size (wider sample size is required to confirm this re-
sults), a lack shared with other similar studies. For this 
reason, more homogeneous studies with bigger sample 
sizes are needed to determine the relationship between 
HPV infection in these two areas.
Regarding the present study’s first secondary objec-
tive (to determine the concordance between genital and 
oral types in sexually active women with HPV-related 
CIN), among 22 women with genital HPV-16, only one 
(4.54%) also presented oral HPV-16; while for the other 
92 HPV genital types, no concordance was found with 
oral types of HPV. Similar findings have been reported 
by authors such as Sayyah-Melli et al., (27) who geno-
typed by PCR the HPV-DNA in the saliva of 104 sexu-
ally active women with HPV-related genital lesions for 
types 16, 18, 31, 33 (high risk) and 6, and 11 (low risk), 
observing greater genital/oral concordance for HPV-16 
type, this being higher than in the present study (10.6%). 
Vogt et al., (28) obtained similar results in a study of 
37 different types of HPV-DNA in saliva, obtaining 
a concordance of HPV genital and oral types of 12%. 
Smith et al., (29) investigating the possible concordance 
between genital and oral HPV types in a total of 577 
pregnant women (without HPV-related CIN) found that 
HPV prevalence was 29% in the cervix and 2.4% in the 
oral cavity, and that there was no type-specific HPV 
concordance between these two sites. One explanation 
for the lack of concordance between the oral and genital 
sites may be due to non-persistent or intermittent detec-
tion of HPV over time, as shown in studies of the cervix 
(30). This phenomenon of intermittent HPV detection 
over time has not been studied in relation to the oral cav-
ity. Perhaps oral and genital specimens need to be col-
lected at multiple intervals to detect fluctuating levels 
of infection in an individual, although it is questionable 
whether repeat measurements would reduce differences 
in prevalence rates at the two mucosal sites. Neverthe-
less, although longitudinal studies could obtain some 
modification of the low concordance of genital and oral 
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HPV types, it is unclear to what extent differences be-
tween the two sites would be reduced (29).
Regarding the present study’s second secondary objec-
tive (to determine whether sexual behaviors have an 
influence on the presence of HPV-related CIN), it was 
found that marital status, age at first intercourse, num-
ber of lifetime sexual partners, and condom use were 
related to the presence of HPV-related CIN (p<0.001; 
p=0.017; p=0.002; and p<0.001 respectively). Similar 
results were obtained by authors such as Saini et al., 
(21), who, in their study of 70 sexually active women 
with cervical cancer, found that 17.1% were not married 
or not in stable relationships. Others such as Smith et 
al., (29) in their study of 577 pregnant women (without 
HPV-related CIN), found an HPV prevalence of 29% in 
the cervix in a multiple logistic regression model con-
sidering the binary “presence of HPV in cervix” as the 
outcome variable, and using marital status, age at first 
intercourse, and number of lifetime sexual partners as 
covariates; they found that these variables related to 
sexual behavior did exert an influence on “presence 
of HPV in cervix.” Similarly, Schlecht et al., (26), in a 
study of the influence of sexual behaviors on the pres-
ence of genital HPV in a sample of 645 sexually active 
women, also found that marital status, age at first inter-
course, number of lifetime sexual partners, and condom 
use, were covariates closely related to cervical HPV in-
fection. Both the present results and those of the other 
authors cited above point to a need for greater social 
awareness of: multi-type prophylactic HPV vaccines, 
continued screening strategies to prevent HPV-related 
diseases, and the need for sexual healthcare information 
targeted at sexually active women.
Regarding the present study’s third secondary objective 
(to determine whether sexual behaviors influence the 
presence of oral HPV), the use or not of condoms was 
strongly related to the presence of oral HPV (p<0.001). 
Similar results were obtained by Schlecht et al., (26), 
who in their study of the influence of sexual behaviors 
on the presence of genital and oral HPV among a sam-
ple of 645 sexually active women, found that condom 
use or non-use during oral-to-genital sex were closely 
related to the presence of oral HPV. In the same way, 
Ragin et al., (25) in their study of the prevalence of oral 
HPV in 118 sexually active women, found that 66.6% 
of women with oral HPV practiced oral-to-genital sex 
(58.3% with men and 8.3% with women) without using 
a condom, so that non-use of this preventative measure 
was significantly related to the presence of HPV in the 
oral cavity (p=0.039). The results of the present study 
analyzed by means of a logistic regression model found 
that the practice of oral-to-genital sex showed no rela-
tion to the presence of oral HPV (p=0.288), but the use 
or non-use of condoms did  (p<0.001) indicating that 
oral-to-genital sex does not increase the risk of oral 
HPV infection providing a condom is used.
In conclusion, this study shows that the prevalence of 
HPV-DNA in the saliva of sexually active women with 
HPV-related CIN is similar to that of healthy control 
subjects and that the concordance between genital and 
oral HPV types is low, which may indicate that the nat-
ural history of oral and cervical infection differs; both 
the presence of cervical pathology and the presence of 
oral HPV are related to sexual behaviors. Nevertheless, 
wider sample size is required to confirm this results.
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